General
Preferred name
BAVISANT
Synonyms
Bavisant (dihydrochloride) ()
JNJ-31001074 ()
Bavisant (dihydrochloride hydrate) ()
JNJ31001074AAC ()
JNJ31001074 (dihydrochloride hydrate) ()
BAVISANT DIHYDROCHLORIDE ()
Bavisant dihydrochloride hydrate ()
JNJ-31001074-AAC ()
Bavisant dihydrochloride monohydrate ()
Ben-2001 ()
P&D ID
PD058151
CAS
929622-08-2
1103522-80-0
929622-09-3
Tags
available
drug candidate
Drug indication
Attention deficit hyperactivity disorder
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].
PRICE 103
DESCRIPTION Bavisant is a highly selective, orally active antagonist of the human H3 receptor. It is a novel mechanism of action, involving wakefulness and cognition. It has potential to be used as a treatment for ADHD. It was developed by Johnson & Johnson and has completed a phase II ADHD trial, but there has been no progress. (BOC Sciences Bioactive Compounds)
DESCRIPTION Bavisant (JNJ-31001074) is a selective and orally active Human H3 receptor antagonist. Bavisant can be used in research on mechanisms of action, involving wakefulness and cognition and the treatment for ADHD. (TargetMol Bioactive Compound Library)
DESCRIPTION The dihydrochloride hydrate salt form of Bavisant which is an orally bioavaliable and selective H3 receptor antagonist that could probably useful in the treatment of Attention-deficit hyperactivity disorder(ADHD). It is known to have been completed the Ph (BOC Sciences Bioactive Compounds)
DESCRIPTION Bavisant dihydrochloride is the dihydrochloride form of Bavisant, which is a highly selective, orally active antagonist of the human H3 receptor. It may be used as a treatment for ADHD. It was developed by Johnson & Johnson and has completed a phase II ADHD trial, but there has been no progress. (BOC Sciences Bioactive Compounds)
Compound Sets
8
BOC Sciences Bioactive Compounds
bavisant-cas-929622-08-2-item-460641
bavisant-dihydrochloride-hydrate-cas-1103522-80-0-item-474345
bavisant-dihydrochloride-cas-929622-09-3-item-474919
ChEMBL Drugs
CHEMBL2103862
CHEMBL2105715
Drug Repurposing Hub
DrugBank
DB12299
DrugMAP
DM6CVZ5
MedChem Express Bioactive Compound Library
HY-14880
HY-14880B
ReFrame library
TargetMol Bioactive Compound Library
TQ0046
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
329.21
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
1
cLogP
1.44
TPSA
36.02
Fraction CSP3
0.63
Chiral centers
0.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Histamine Receptor
HRH3
Human H3 receptor
Pathway
Immunology/Inflammation
GPCR/G protein
Neuronal Signaling
Neuroscience
MOA
Histamine Receptor antagonist
Solubility
10 mM in DMSO
Source data